On May 18, Parabilis Medicines announced a collaboration with Regeneron to develop therapies using the Helicon peptide platform. The agreement includes a $50 million upfront payment and a $75 million equity commitment from Regeneron. Potential milestone payments could reach up to $2.2 billion plus tiered royalties.
